MobiHealth News September 23, 2021
The partnership aims to investigate the role genetics play in developing personalised cancer treatments.
King’s College London and global pharmaceutical company, GlaxoSmithKline (GSK), have formed a new five-year partnership to use AI to provide insight into why and how some patients respond to certain cancer treatments.
WHY IT MATTERS
The collaboration will use AI systems to build tools that will support clinical decision-making to help improve patient outcomes.
This move has resulted in the Translational Oncology Research Hub, a research collaboration between the Artificial Intelligence and Experimental Medicine Units at GSK and the Comprehensive Cancer Centre at King’s College London.
The project will help create a personalised care strategy for a range of cancer patients, including those at high-risk of...
Today's Sponsors
Today's Sponsor